Cecilia Brown

DocwireNews

Tezepelumab led to significant reductions in asthma exacerbation rates over placebo in patients with severe uncontrolled asthma, according to a recent pooled analysis of clinical trials.Zaid Zoumot, MBBS, MSc, PhD, FRCP, of the Respiratory Institute at Cleveland Clinic Abu Dhabi, and colleagues conducted the systematic review and meta-analysis of randomized controlled trials to evaluate the safety and efficacy of tezepelumab.The 6 randomized controlled trials included 2667 patients with severe uncontrolled asthma, 1610 of whom received tezepelumab and 1057 of whom received placebo. Dr. Zoumot and colleagues assessed the impact of the treatment on forced expiratory volume in 1 second, the rate of asthma exacerbations, health-related quality of life, fractional exhaled nitric oxide, and blood eosinophil count.Tezepelumab improved forced expiratory volume in 1 second by 0.15 L and reduced the asthma exacerbation rate by 0.60 a year compared with placebo. It also led to a decrease of 12.41 parts per billion of fractional exhaled nitric oxide compared with placebo. The improvements in forced expiratory volume in 1 second and fractional exhaled nitric oxide were maintained at 24 weeks and 52 weeks.The incidence of adverse drug reactions was similar between patients receiving tezepelumab and placebo.&ldquo;Our meta-analysis results demonstrated that tezepelumab showed significant reduction of the asthma exacerbation rates compared to the pooled placebo,&rdquo; Dr. Zoumot and colleagues concluded. &ldquo;This observation was in contrast to a previously published meta-analysis where tezepelumab did not show statistically significant improvement of the exacerbation rate compared to the pooled placebo, mainly due to the lower number of included trials (n = 1).&rdquo;Zoumot Z, Al Busaidi N, Tashkandi W, et al. Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis. J Asthma Allergy. 2022;15:1665-1679. doi:10.2147/JAA.S378062

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Tezepelumab Reduces Asthma Exacerbation Rates in Pooled Analysis

Asthma

Tezepelumab led to significant reductions in asthma exacerbation rates over placebo in patients with severe uncontrolled asthma, according to a recent pooled analysis of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe